Skip to main content

Table 1 Clinical and laboratory characteristics of patients with POEMS syndrome

From: Pulmonary manifestations of POEM syndrome: a retrospective analysis of 282 cases

 

ALL

male

female

N, (%)

282 (100.0)

158 (56.0)

124 (44.0)

Age, years

48.7 ± 10.8

48.7 ± 11.6

48.6 ± 9.8

Smoking, N (%)

71 (25.2)

70 (44.3)

1 (0.8)

Alcohol, N (%)

40 (14.2)

39 (24.7)

1 (0.8)

Respiratory symptoms

   

 Dyspnea, N (%)

97 (34.4)

29 (18.4)

32 (25.8)

 Chest tightness, N (%)

61 (21.6)

47 (29.7)

50 (40.3)

 Orthopnea, N (%)

46 (16.3)

15 (9.5)

31 (25)

 Cough, N (%)

15 (5.3)

8 (5.1)

7 (5.6)

Comorbidities

   

 Hypertension, N (%)

78 (27.7)

43 (27.2)

35 (28.2)

 Cardiac disease, N (%)

14 (5)

12 (7.6)

2 (1.6)

 Diabetes, N (%)

37 (13.1)

25 (15.8)

12 (9.7)

 Cancer, N (%)

5 (1.8)

2 (1.3)

3 (2.4)

POEMS manifestations

   

 Polyneuropathy, N (%)

264 (93.6)

148 (93.7)

116 (93.5)

 Organomegaly, N (%)

260 (92.2)

141 (89.2)

119 (96)

 Endocrinopathy, N (%)

246 (87.2)

145 (91.8)

101 (81.5)

 Monoclonal gammopathy, N (%)

245 (86.9)

135 (85.4)

110 (88.7)

 Skin changes, N%

245 (86.9)

138 (87.3)

107 (86.3)

 Bone lesions, N (%)

158 (56)

100 (63.3)

58 (46.8)

 Peripheral oedema, N (%)

218 (77.3)

117 (74.1)

101 (81.5)

 Papilledema, N (%)

100 (35.5)

49 (31)

51 (41.1)

 Castleman disease, N (%)

41 (14.5)

14 (8.9)

27 (21.8)

Laboratory test results

   

 Albumin, g/L

35.1 ± 5.8

35.2 ± 6.0

35.0 ± 5.7

 LDH, U/L

133.5 ± 43.8

139.5 ± 50.7

125.9 ± 31.7

 IL-6, pg/mL

6.2 (3.5–13.1)

6.2 (3.4–11.8)

6.65 (3.6–13.8)

 TNF-α, pg/mL

13.9 (10.4–20.6)

15.4 (11.1–21.1)

11.8 (9.6–20.5)

 C3, g/L

0.9 ± 0.2

0.9 ± 0.2

1.0 ± 0.2

 C4, g/L

0.2 ± 0.1

0.2 ± 0.1

0.2 ± 0.1

 β-CTX, ng/ml

1.2 (0.8–1.7)

1.2 (0.8–1.8)

1.1 (0.8–1.6)

 KAP, %

7 (2.5)

4 (2.5)

3 (2.4)

 LAM, %

235 (83.3)

130 (82.3)

105 (84.7)

 VEGF > 1200 pg/mL, %

241 (85.5)

133 (84.2)

108 (87.1)

Duration of diagnosis, years

1.3 (0.6–2)

1.2 (0.6–2.0)

1.3 (0.6–2)

Length of stay, days

10.0 (4.0–21.3)

9.0 (4.0–21.0)

12.5 (5.0–23.0)

  1. LDH lactatedehydrogenase, IL-6 interleukin 6, TNF-α tumor necrosis factor α, C3 complement component 3, C4 complement component 4, β-CTX β-type I collagen carboxyterminalpeptide, KAP Kappa light chain, LAM Lambda light chain, VEGF vascular endothelial growth factor